Navigation Links
Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice

that these MDIs are functional in vitro and when transplanted into stz-induced NOD/SCID mice is a breakthrough for our adult stem cell program. The differentiation of MDIs derived from MDSCs produced from type 1 and type 2 diabetics is a major advance in the development of a cell replacement therapy for the treatment of diabetes."

"These presentations by Dr. Winnier demonstrate significant advancement of our stem cell development program and serve as proof-of-principle for our adult diabetes mellitus beta-cell replacement therapy development", said David McWilliams, chief executive officer. "The potential use of adult MDSCs for the development of functional MDIs maybe a viable alternative to the development of islet cells derived from embryonic stem cells."

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forwa
'"/>




Page: 1 2 3

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Monitoring Patient Glucose Levels: New Advances in software make it easier
5. New Advances in Gastric Diagnostics: Smaller is Better
6. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
7. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
8. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
(Date:9/4/2008)...X-351 awarded orphan designation for the treatment...eukemia, PRINCETON, N.J., Sept. 4 /-...U.S. Food & Drug Administration (FDA) has granted ...norubicin) Liposome Injection,for the treatment of...tly preparing to conduct two randomized Phase 2,st...
(Date:9/4/2008)...her Roche first in TaqMan(R) real-time PCR testing... lab, PLEASANTON, Calif., Sept. 4 /PRNewswire/ ...pproved the Roche COBAS(R) TaqMan(R) HBV Test,the...A approved in the U.S.,The test uses Roche,s real-...titis B virus DNA in a patient,s blood. Doctors ma...
(Date:9/4/2008)...ractice Bulletin for Obstetrician-Gynecologists St...ice Change-Minimally Invasive Interventional,Radio... With Uterine,Fibroids, FAIRFAX, Va., Sept. 4 /PR...nal Radiology, a national organization of nearly 4...ionals dedicated to improving health,care through ...
(Date:9/4/2008)...tal Study Seeks to Enroll 750 Women at More Than 1...- QuatRx Pharmaceuticals, a,privately...ment and,commercialization of compounds to treat e...today announced that it has initiated a second,Pha...ets), the company,s,estrogen-free oral therapy in ...
Breaking Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 1NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 2NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 4Steroids Seem Safe for Babies at Risk of Early Birth 1618 1Steroids Seem Safe for Babies at Risk of Early Birth 1618 2Steroids Seem Safe for Babies at Risk of Early Birth 1618 3Pennsylvania Needs More Lung Cancer Research 1615 1STAAR Surgical Reports Operational Progress 1612 1STAAR Surgical Reports Operational Progress 1612 2STAAR Surgical Reports Operational Progress 1612 3STAAR Surgical Reports Operational Progress 1612 4
...IRE)--Apr 30, 2007 - CollaGenex,Pharmaceuticals, I...t in the May 2007 issue of the Journal of the Amer...zed phase III clinical trials,demonstrated the ef...cline (Oracea(R), 40-mg doxycycline, USP capsules)...cluded these studies,establish the first important...
...IRE)--Apr 30, 2007 - Hemispherx Biopharma,Inc. (A...lication,(Journal of Immunology, April 2007) that ...proprietary experimental therapeutic,Ampligen(R) ...g,tested as a monotherapy for Chronic Fatigue Synd...s., The new peer-reviewed study shows conclusively...
Other Medicine Technology:Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4New Report Illuminates Ampligen's Unique Mechanism of Action 2New Report Illuminates Ampligen's Unique Mechanism of Action 3New Report Illuminates Ampligen's Unique Mechanism of Action 4
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: